Trial Profile

Randomised, double blind, multicenter Phase II Clinical Trial of NLY01 for Alzheimer's Disease

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegylated exenatide (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Therapeutic Use

Most Recent Events

02 Nov 2020 According to a Neuraly Inc media release, topline results of this study are expected by Q4, 2023.
02 Nov 2020 According to a Neuraly Inc media release, the company announced that it has received clearance of an investigational new drug application (IND) to initiate this study.
16 Aug 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com